These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 33548185)

  • 1. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
    de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
    van Wifferen F; de Jonge L; Worthington J; Greuter MJE; Lew JB; Nadeau C; van den Puttelaar R; Feletto E; Yong JHE; Lansdorp-Vogelaar I; Canfell K; Coupé VMH;
    J Med Screen; 2022 Jun; 29(2):72-83. PubMed ID: 35100894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening.
    Worthington J; van Wifferen F; Sun Z; de Jonge L; Lew JB; Greuter MJE; van den Puttelaar R; Feletto E; Lansdorp-Vogelaar I; Coupé VMH; Ein Yong JH; Canfell K;
    EClinicalMedicine; 2023 Aug; 62():102081. PubMed ID: 37538541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-related disruptions to colorectal cancer screening, diagnosis, and treatment could increase cancer Burden in Australia and Canada: A modelling study.
    Worthington J; Sun Z; Fu R; Lew JB; Chan KKW; Li Q; Eskander A; Hui H; McLoughlin K; Caruana M; Peacock S; Yong JHE; Canfell K; Feletto E; Malagón T
    PLoS One; 2024; 19(4):e0296945. PubMed ID: 38557758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study.
    Luo Q; O'Connell DL; Yu XQ; Kahn C; Caruana M; Pesola F; Sasieni P; Grogan PB; Aranda S; Cabasag CJ; Soerjomataram I; Steinberg J; Canfell K
    Lancet Public Health; 2022 Jun; 7(6):e537-e548. PubMed ID: 35660215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada.
    Yong JH; Mainprize JG; Yaffe MJ; Ruan Y; Poirier AE; Coldman A; Nadeau C; Iragorri N; Hilsden RJ; Brenner DR
    J Med Screen; 2021 Jun; 28(2):100-107. PubMed ID: 33241760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia.
    Nickson C; Smith MA; Feletto E; Velentzis LS; Broun K; Deij S; Grogan P; Hall M; He E; St John DJ; Lew JB; Procopio P; Simms KT; Worthington J; Mann GB; Canfell K
    Elife; 2023 Apr; 12():. PubMed ID: 37022767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.
    Breekveldt ECH; Lansdorp-Vogelaar I; Toes-Zoutendijk E; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Nagtegaal ID; Krul MF; Kok NFM; Kuhlmann KFD; Vink GR; van Leerdam ME; Elferink MAG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):60-68. PubMed ID: 34822762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the impact of the coronavirus pandemic on bowel cancer screening outcomes in England: A decision analysis to prepare for future screening disruption.
    Mandrik O; Chilcott J; Thomas C
    Prev Med; 2022 Jul; 160():107076. PubMed ID: 35526674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands.
    Dinmohamed AG; Cellamare M; Visser O; de Munck L; Elferink MAG; Westenend PJ; Wesseling J; Broeders MJM; Kuipers EJ; Merkx MAW; Nagtegaal ID; Siesling S
    J Hematol Oncol; 2020 Nov; 13(1):147. PubMed ID: 33148289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cancer screening restart strategies after COVID-19 disruption.
    Kregting LM; Kaljouw S; de Jonge L; Jansen EEL; Peterse EFP; Heijnsdijk EAM; van Ravesteyn NT; Lansdorp-Vogelaar I; de Kok IMCM
    Br J Cancer; 2021 Apr; 124(9):1516-1523. PubMed ID: 33723386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe.
    Toes-Zoutendijk E; Portillo I; Hoeck S; de Brabander I; Perrin P; Dubois C; van Leerdam M; Lansdorp-Vogelaar I; Bardou M
    J Med Screen; 2020 Jun; 27(2):68-76. PubMed ID: 31645173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact and Recovery from COVID-19-Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis.
    van den Puttelaar R; Lansdorp-Vogelaar I; Hahn AI; Rutter CM; Levin TR; Zauber AG; Meester RGS
    Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):22-29. PubMed ID: 36215205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial.
    Forsberg A; Westerberg M; Metcalfe C; Steele R; Blom J; Engstrand L; Fritzell K; Hellström M; Levin LÅ; Löwbeer C; Pischel A; Strömberg U; Törnberg S; Wengström Y; Ekbom A; Holmberg L; Hultcrantz R;
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):513-521. PubMed ID: 35298893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic.
    Kortlever TL; de Jonge L; Wisse PHA; Seriese I; Otto-Terlouw P; van Leerdam ME; Spaander MCW; Dekker E; Lansdorp-Vogelaar I
    Prev Med; 2021 Oct; 151():106643. PubMed ID: 34217421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic.
    Issaka RB; Taylor P; Baxi A; Inadomi JM; Ramsey SD; Roth J
    JAMA Netw Open; 2021 Apr; 4(4):e216454. PubMed ID: 33843997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of Microsimulation Models against Alternative Model Predictions and Long-Term Colorectal Cancer Incidence and Mortality Outcomes of Randomized Controlled Trials.
    Lew JB; Greuter MJE; Caruana M; He E; Worthington J; St John DJ; Macrae FA; Feletto E; Coupé VMH; Canfell K
    Med Decis Making; 2020 Aug; 40(6):815-829. PubMed ID: 32845232
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.